Scarica l'app Stockscreener
82.27
0.42%
-0.35
Dopo l'orario di chiusura:
82.66
0.39
+0.47%
Precedente Chiudi:
$82.62
Aprire:
$83.3
Volume 24 ore:
1.76M
Relative Volume:
1.12
Capitalizzazione di mercato:
$4.01B
Reddito:
-
Utile/perdita netta:
$-192.89M
Rapporto P/E:
-21.11
EPS:
-3.8976
Flusso di cassa netto:
$-172.97M
1 W Prestazione:
-6.50%
1M Prestazione:
-17.69%
6M Prestazione:
-29.83%
1 anno Prestazione:
+497.46%
Intervallo 1D:
$81.01
$85.05
Intervallo di 1 settimana:
$81.01
$92.66
Portata 52W:
$34.30
$151.02
Celcuity Inc Stock (CELC) Company Profile
Nome
Celcuity Inc
Settore
Industria
Telefono
763-392-0767
Indirizzo
16305 36TH AVENUE N, MINNEAPOLIS, MN
Compare CELC vs VRTX, REGN, ARGX, RVMD, ALNY
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CELC
Celcuity Inc
|
82.27 | 4.03B | 0 | -192.89M | -172.97M | -3.8976 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Celcuity Inc Stock (CELC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-27 | Iniziato | Citizens | Mkt Outperform |
| 2025-12-12 | Iniziato | Wells Fargo | Overweight |
| 2025-11-18 | Iniziato | Wolfe Research | Outperform |
| 2025-11-17 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-09-22 | Iniziato | Guggenheim | Buy |
| 2025-07-01 | Ripresa | Stifel | Buy |
| 2024-07-22 | Iniziato | Leerink Partners | Outperform |
| 2024-02-22 | Iniziato | Stifel | Buy |
| 2023-12-08 | Iniziato | H.C. Wainwright | Buy |
| 2021-10-08 | Iniziato | Canaccord Genuity | Buy |
| 2021-09-07 | Iniziato | Jefferies | Buy |
| 2021-07-29 | Iniziato | Cowen | Outperform |
| 2021-07-27 | Iniziato | Needham | Buy |
| 2021-01-28 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-24 | Reiterato | H.C. Wainwright | Buy |
| 2020-05-11 | Ripresa | Craig Hallum | Buy |
| 2018-11-20 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Celcuity Inc Borsa (CELC) Ultime notizie
Celcuity Inc. (CELC) Investigation: Bronstein, Gewirtz & Grossman - The National Law Review
Celcuity Inc (CELC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Celcuity Inc (CELC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Bronstein, Gewirtz & Grossman, LLC Is Investigating Celcuity Inc. (CELC) And Encourages Investors to Connect - ACCESS Newswire
Celcuity Inc (CELC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Celcuity Inc (CELC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CELC6137628 Bond Risk Profile - TradingView
Celcuity Inc. Revenue Breakdown – NASDAQ:CELC - TradingView
Bronstein, Gewirtz & Grossman, LLC Encourages Celcuity Inc. (CELC) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
ETFs Investing in Celcuity Inc. Stocks - TradingView
Celcuity's Gedatolisib: Regulatory Win Meets Commercial Reality - Kavout | AI
CELC Stock Jumps After Hours On Positive Breast Cancer Trial Data - Stocktwits
Celcuity Inc. (CELC) Investor Outlook: Analyzing an 85% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
Celcuity Inc (CELC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Celcuity Inc. (CELC) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Celcuity Inc. (CELC) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Celcuity's Revtorpyk approval fuels blockbuster expectations - S&P Global
CELC Stock Clocks Best Day In About 2 Months On First FDA Approval For Cancer Drug - Stocktwits
Price to sales forward of Celcuity Inc. – NASDAQ:CELC - TradingView
Celcuity faces securities fraud probe after FDA delays breast cancer drug launch, shares drop 17.6%. - Pluang
2026-07-23 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Celcuity Inc. (CELC) and Encourages Investors to Learn More About the Investigation | NDAQ:CELC | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Is Investigating Celcuity Inc. (CELC) And Encourages Stockholders to Connect - ACCESS Newswire
With FDA approval, Celcuity sees big future for its new breast cancer drug - Star Tribune
Celcuity Inc. (CELC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
CELCUITY ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
CELCUITY ALERT: Bragar Eagel & Squire, P.C. is Investigating Celcuity Inc. on Behalf of Celcuity Stockholders and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
Why CELC Stock Declined 15% in a Week Despite a Major FDA Win - Yahoo Finance
CELC stock clocks best day in about 2 months on first FDA approval for cancer drug - MSN
Celcuity (CELC) Is Down 17.4% After FDA Clears First-in-Class REVTORPYK Combo for HR+ Breast Cancer - Sahm
Celcuity falls as rollout concerns overshadow FDA approval of breast cancer drug - MSN
Kirby McInerney LLP investigates Celcuity for p... - Pluang
CELC INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Encourages Celcuity Inc. (CELC) Investors to Inquire about Securities Investigation - ACCESS Newswire
Celcuity (CELC) Stock May Be Overvalued After REVTORPYK Approval - webull.com
Celcuity (CELC) Receives a Buy from Leerink Partners - The Globe and Mail
Precision Trading with Celcuity Inc. (CELC) Risk Zones - Stock Traders Daily
Celcuity got its cancer drug approved. Then its stock dipped - Endpoints News
Form 4 Celcuity LLC For: 16 July By Investing.com - Investing.com Nigeria
Form 13D/A Celcuity Inc. For: 16 July By Investing.com - Investing.com Nigeria
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Celcuity Inc.CELC - PR Newswire
Baker Bros. Advisors LP sells $317.75m Celcuity shares at $102.50 - Investing.com Nigeria
Baker Bros. Advisors LP sells $317.75m Celcuity shares at $102.50 By Investing.com - Investing.com South Africa
Form 13D/A Celcuity Inc. For: 16 July - Investing.com India
Craig-Hallum Sticks to Their Buy Rating for Celcuity (CELC) - The Globe and Mail
A Quick Look at Today's Ratings for Celcuity(CELC.US), With a Forecast Between $155 to $178 - Moomoo
Celcuity's REVTORPYK Approval: A Multi-Billion Dollar Breakthrough Despite High Expectations - Kavout | AI
Celcuity (CELC) Experiences Significant Decline - GuruFocus
Celcuity’s First-in-Class Drug Gets FDA Approval in Most Common Type of Breast Cancer - MedCity News
Celcuity shares fall as launch delay eclipses US approval for breast cancer drug - Classic Rock 103.5 WIMZ
Why This Biotech Stock, With Its First FDA Approval, Just Crashed By Double Digits - Investor's Business Daily
Celcuity Inc Azioni (CELC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.97%
0.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):